title: Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study.
abstract: Thrombopoietin receptor agonists, which raise platelet counts in patients with chronic immune thrombocytopenia, may be associated with increases in bone marrow (BM) reticulin. Patients with chronic immune thrombocytopenia participating in the Eltrombopag Extended Dosing (EXTEND) study underwent BM biopsies to identify clinically relevant BM fibrosis-related increases. Specimens were centrally reviewed by 2 hematopathologists. Two hundred thirty-two biopsy specimens were collected from 117 patients treated for ≤5.5 years. Moderate to marked reticulin fibrosis was found in 2 patients. After withdrawing from the study, the biopsy of 1 patient reverted to normal. There were no other pathologic changes identified among on-treatment specimens, and no pattern of abnormal reticulin deposition associated with eltrombopag treatment was evident.
authors: Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.
authors: Russell K
authors: RK
authors: Brynes
authors: Department of Pathology, Weill Medical College of Cornell University, New York, New York.
authors: Attilio
authors: A
authors: Orazi
authors: GlaxoSmithKline, Research Triangle Park, North Carolina.
authors: Dickens
authors: D
authors: Theodore
authors: GlaxoSmithKline, Stockley Park, United Kingdom.
authors: Paul
authors: P
authors: Burgess
authors: GlaxoSmithKline, Collegeville, Pennsylvania.
authors: Christine K
authors: CK
authors: Bailey
authors: Department of Pathology, Keck School of Medicine, University of Southern California, Los Angeles, California.
authors: Maung M
authors: MM
authors: Thein
authors: GlaxoSmithKline, Collegeville, Pennsylvania.
authors: Kalpana K
authors: KK
authors: Bakshi
mesh_terms: D000328:Adult; D001565:Benzoates / Q000008:administration & dosage* / Q000009:adverse effects; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D001856:Bone Marrow Examination; D002908:Chronic Disease; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006834:Hydrazines / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010976:Platelet Count; D055728:Primary Myelofibrosis / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000473:pathology; D011720:Pyrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D053628:Receptors, Thrombopoietin / Q000037:antagonists & inhibitors; D012155:Reticulin / Q000378:metabolism*
chemical_list: D001565:Benzoates; D006834:Hydrazines; D011720:Pyrazoles; D053628:Receptors, Thrombopoietin; D012155:Reticulin; C520809:eltrombopag